Co-morbidities

Andrew McRae ,

Read time: 10 Mins

Silvio Inzucchi, Andrew JS Coats, Richard Hobbs, et al

Stefan Anker, Javed Butler, Shelley Zieroth, et al

Stefan Anker, Javed Butler, Shelley Zieroth, et al

Maria Stefil , Matthew Dixon , Jameela Bahar , et al

Read time: 21 Mins

Andrew JS Coats,

Paul Kalra,

Watch time: 12m 40s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 4m (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

Mauro Gori , Emilia D’Elia , Edoardo Sciatti , et al

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 1h 3m (4 videos)
HF 22: SCD Risk Protection for Newly Diagnosed HF Patients

José González-Costello,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 4m (6 videos)

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 1h 3m (4 videos)

Giuseppe Rosano , David Quek , Felipe Martínez ,

John JV McMurray, Stefan Anker, , et al

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

Shelley Zieroth, , , et al

Ovidiu Chioncel , Sean P Collins , Andrew P Ambrosy , et al

Andrew JS Coats, Stefan Anker,

About

Comorbidities frequently accompany chronic heart failure, contributing to increased morbidity and mortality, and an impaired quality of life. Extreme comorbidity is significantly more common in patients with chronic heart failure due to left ventricular systolic dysfunction. The efficient management of such complexity requires the integration of general and specialist expertise.

Media

Silvio Inzucchi, Andrew JS Coats, Richard Hobbs, et al

Stefan Anker, Javed Butler, Shelley Zieroth, et al

Stefan Anker, Javed Butler, Shelley Zieroth, et al

Paul Kalra,

Watch time: 12m 40s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 4m (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 1h 3m (4 videos)

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Lars H Lund, James L Januzzi, Justin Ezekowitz, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, , , et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Andrew JS Coats, Harriette Van Spall, Faiez Zannad, et al

Shelley Zieroth, Stefan Anker,

EASD 2019: The DEFINE-HF trial - Dr Mikhail N Kosiborod

Mikhail Kosiborod,

Media

Silvio Inzucchi, Andrew JS Coats, Richard Hobbs, et al

Stefan Anker, Javed Butler, Shelley Zieroth, et al

Stefan Anker, Javed Butler, Shelley Zieroth, et al

Andrew JS Coats,

Paul Kalra,

Watch time: 12m 40s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 4m (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 1h 3m (4 videos)
HF 22: SCD Risk Protection for Newly Diagnosed HF Patients

José González-Costello,

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Lars H Lund, James L Januzzi, Justin Ezekowitz, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, , , et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

John JV McMurray, Stefan Anker, , et al

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

AHA 2020: EMPA-TROPISM Trial Results — Dr Juan Badimon

Andrew JS Coats, Harriette Van Spall, Faiez Zannad, et al

ESC 2020: Commentary on the EMPEROR-Reduced Study — Dr Giuseppe Galati

Giuseppe Galati,

Articles

Pharmacy Challenges in Cardiac Care During COVID-19: Lessons Learnt

Andrew McRae

,

Published:

02 February 2023

Citation:

Cardiac Failure Review 2023;9:e03.

DOI:

https://doi.org/10.15420/cfr.2022.20
  • Views: Views 35
  • Downloads: Downloads 2
  • Read time: 10 Mins

Polypharmacy in Older People With Heart Failure

Maria Stefil

,

Matthew Dixon

,

Jameela Bahar

,

Schabnam Saied

,

Knievel Mashida

,

Olivia Heron

,

Eduard Shantsila

,

Lauren Walker

,

Asangaedem Akpan

,

Gregory YH Lip

,

Rajiv Sankaranarayanan

,

Published:

19 December 2022

Citation:

Cardiac Failure Review 2022;8:e34.

DOI:

https://doi.org/10.15420/cfr.2022.14
  • Views: Views 557
  • Downloads: Downloads 35
  • Read time: 21 Mins

SGLT2i in HFpEF

Mauro Gori

,

Emilia D’Elia

,

Edoardo Sciatti

,

Michele Senni

,

Published:

08 July 2022

Citation:

Cardiac Failure Review 2022;8:e26.

DOI:

https://doi.org/10.15420/cfr.2022.04
  • Views: Views 2244
  • Downloads: Downloads 219
  • Citations: 2

Medical Treatment of HFrEF in the Elderly

Ivan Milinkovic

,

Marija Polovina

,

Andrew JS Coats

,

Giuseppe Rosano

,

Petar M Seferovic

,

Published:

09 May 2022

Citation:

Cardiac Failure Review 2022;8:e17.

DOI:

https://doi.org/10.15420/cfr.2021.14
  • Views: Views 1927
  • Downloads: Downloads 189